AVR

Anteris Technologies Global Corp

6.05

Oct 16 • 3:59 PM ET -0.31 (-4.87%)

6.05

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Medical Devices USA Small NASD

Peers: EW ICUI MMSI TFX BAX BDX BSX MDT SYK GKOS

| Held by: IWM VXF IWN VTWO SCHA XHE IWC VFMO FESM ITOT

Scroll to Statements

Index	RUT
Market Cap	589.62M
Enterprise Value	335.84M
Income	-103.56M
Sales	2.24M
Book/sh	2.58
Cash/sh	2.64
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	174
IPO	Dec 13, 2024

P/E	-
Forward P/E	-
PEG	-
P/S	263.22
P/B	2.34
P/C	2.29
P/FCF	-
EV/EBITDA	-
EV/Sales	149.93
Quick Ratio	14.20
Current Ratio	14.20
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	-1.94
EPS next Y	-1.22
EPS next Q	-0.31
EPS this Y	52.71%
EPS next Y	-0.90%
EPS next 5Y	27.39%
EPS past 3/5Y	-44.21% -
Sales past 3/5Y	-15.77% -
EPS Y/Y TTM	16.73%
Sales Y/Y TTM	-9.56%
EPS Q/Q	48.26%
Sales Q/Q	63.27%
Earnings	Aug 10 AMC
EPS/Sales Surpr.	-44.72% -32.73%

Insider Own	16.60%
Insider Trans	-8.19%
Inst Own	74.10%
Inst Trans	-5.39%
ROA	-66.31%
ROE	-75.10%
ROIC	-40.82%
Gross Margin	-2.54%
Oper. Margin	-4738.36%
Profit Margin	-4619.27%
SMA20	-16.12%
SMA50	-26.06%
SMA200	-17.36%
Trades

Shs Outstand	97.41M
Shs Float	81.28M
Short Float	8.21%
Short Ratio	6.94
Short Interest	6.67M
52W High	11.06 -45.27%
52W Low	3.30 83.33%
Volatility	4.51% 4.56%
ATR (14)	0.34
RSI (14)	23.53
Beta	1.88
Rel Volume	1.08
Avg Volume	960.63K
Volume	1,032,918

Perf Week	-10.64%
Perf Month	-28.15%
Perf Quarter	-26.40%
Perf Half Y	-0.33%
Perf YTD	21.24%
Perf Year	21.98%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.83
Target Price	12.84
Prev Close	6.36
Price	6.05
Change %	-4.87%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-07-26	Initiated	Barclays	Equal Weight	$10
Mar-12-26	Resumed	Cantor Fitzgerald	Overweight	$15
Mar-11-26	Initiated	Wells Fargo	Overweight	$16
Jan-08-25	Initiated	Lake Street	Buy	$20
Jan-07-25	Initiated	TD Cowen	Buy	$15
Jan-07-25	Initiated	Cantor Fitzgerald	Overweight	$9
Jan-07-25	Initiated	Barclays	Overweight	$22

Oct-07-26 10:00AM	Flutter upgraded, AppFolio downgraded: Wall Street's top analyst calls (The Fly)
Sep-06-26 07:47PM	Anteris Technologies appoints Brent Moen as chief financial officer (Proactive)
Aug-31-26 02:45PM	Anteris to Present at September Healthcare Investor Conferences (GlobeNewswire)
Aug-11-26 07:22PM	Anteris Technologies advances PARADIGM Trial in June quarter as US patient recruitment gets underway (Proactive)
07:00PM	Anteris Technologies Announces Results for the Second Quarter of 2026 (GlobeNewswire)
07:22PM	Loading…
Jun-08-26 07:22PM	France clearance marks key milestone for Anteris' pivotal PARADIGM Trial (Proactive)
06:00AM	Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance (GlobeNewswire)
May-13-26 08:39AM	Anteris Appoints Susan Knight and Stephen Denaro to its Board of Directors (GlobeNewswire)
May-12-26 09:33PM	Anteris adds Susan Knight, Stephen Denaro to board as company advances heart valve strategy (Proactive)
07:43PM	Anteris advances PARADIGM trial as Q1 cash burn reflects commercialisation push (Proactive)
07:00PM	Anteris Announces Results for the First Quarter of 2026 (GlobeNewswire)
May-06-26 09:45PM	Anteris treats first US patients in DurAVR pivotal trial (Proactive)
09:45PM	Anteris secures US Medicare coverage for PARADIGM Trial as DurAVR study advances (Proactive)
01:40PM	Anteris Technologies enrolls First US patients in global PARADIGM trial for DurAVR heart valve (Proactive)
May-05-26 08:11PM	Small Cap Watch: Small Ordinaries edges higher as company news flow continues (Proactive)
06:00AM	Loading…
06:00AM	Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial (GlobeNewswire)
Apr-28-26 06:00AM	Anteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM Trial (GlobeNewswire)
Apr-01-26 11:47PM	A new valve, a new playbook: How Anteris is trying to reshape a $10B heart market (Proactive)
Mar-05-26 05:03AM	Anteris Technologies Global Highlights DurAVR TAVR Data, PARADIGM Pivotal Trial Plans at TD Cowen Conference (MarketBeat)
Feb-26-26 06:41PM	Anteris reports US$77.8m 2025 net operating cash outflow as PARADIGM trial gets underway (Proactive)
06:00PM	Anteris Reports 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-23-26 06:30AM	Anteris to Present at Healthcare Investor Conferences TD Cowen and Barclays (GlobeNewswire) +8.45%
Jan-24-26 09:01AM	Anteris Technologies price target lowered to $15 from $20 at Lake Street (TipRanks)
Jan-22-26 04:02PM	Anteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital Raises (GlobeNewswire) +8.42%
04:01PM	Anteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common Stock (GlobeNewswire)
11:28AM	Anteris Technologies announces $200M public offering to fund clinical growth (Proactive)
Jan-21-26 05:50AM	Medtronic to buy up to $90M stake in heart valve developer Anteris (MedTech Dive) +5.39%
01:38AM	What Sparked Anteris Technologies (AVR) Stock Surge Over 52% After-Hours? (Benzinga)
Jan-20-26 10:53PM	Anteris Technologies Global Corp. Announces Pricing of $200 Million Public Offering (GlobeNewswire) +12.52%
04:01PM	Anteris Technologies Global Corp. Announces Proposed $200 Million Public Offering of Common Stock and Strategic Investment from Medtronic (GlobeNewswire)
06:00AM	Loading…
Nov-17-25 06:00AM	Anteris Technologies Presents Data from 100 DurAVR THV Patients at PCR London Valves (GlobeNewswire)
Nov-12-25 05:52PM	Anteris Announces Results for the Third Quarter of 2025 (GlobeNewswire)
Nov-03-25 07:00AM	FDA Approves Anteris's DurAVR THV Global Pivotal Trial (the "PARADIGM Trial") (GlobeNewswire)
Oct-28-25 06:08PM	Anteris DurAVR THV Demonstrates Favorable Hemodynamics in Small Annuli Patients with no Valve Related Mortality at One Year (GlobeNewswire) -7.84% -8.71%
Oct-27-25 05:43PM	Anteris Technologies Announces First Patients Treated in DurAVR THV Global Pivotal Trial (the "PARADIGM Trial") (GlobeNewswire)
08:43AM	Anteris Technologies Announces One-Year Clinical Outcomes for DurAVR THV to be Presented at TCT 2025 (GlobeNewswire)
Oct-15-25 09:18AM	Anteris Receives First European Regulatory Clearance to Commence DurAVR THV Global Pivotal Trial (the "PARADIGM Trial") (GlobeNewswire)
Sep-19-25 02:30AM	Anteris Technologies Global Corp. Announces Adjournment of Special Meeting of Stockholders (GlobeNewswire)
Sep-11-25 08:50AM	Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders (GlobeNewswire)
Sep-04-25 01:42AM	Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders (GlobeNewswire)
Aug-11-25 04:52PM	Anteris Announces Results for the Second Quarter of 2025 (GlobeNewswire) +6.00%
Jul-29-25 10:23AM	Anteris (AVR) Welcomes Two Directors as Major Trial Approaches (Insider Monkey)
Jun-09-25 10:52PM	Anteris Appoints David Roberts and Gregory Moss to its Board of Directors (GlobeNewswire) +13.29%
May-13-25 05:45PM	Anteris Announces Results for the First Quarter of 2025 (GlobeNewswire) -9.89%
Mar-31-25 07:15AM	Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR THV (GlobeNewswire)
Mar-21-25 07:30AM	Anteris Reports One-Year Patient Outcomes for DurAVR THV (GlobeNewswire) -10.16%
Mar-12-25 08:33PM	Anteris Reports 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -6.18%
Feb-28-25 08:00AM	Anteris to Present at Healthcare Investor Conferences - TD Cowen and Barclays (GlobeNewswire)
Dec-16-24 07:49PM	Anteris Technologies Global Corp. Announces Closing of $88.8 Million U.S. Initial Public Offering (Business Wire)
Dec-12-24 10:34PM	Anteris Technologies Global Corp. Announces Pricing of U.S. Initial Public Offering (Business Wire)

Anteris Technologies Global Corp. is a structural heart company, which engages in the development and commercialization of medical devices for heart diseases. It operates through the following geographical segments: United States, Germany, Australia, Switzerland, and Sweden. The company was founded in 1999 and is headquartered in Eagan, MN.

Vice Chairman & CEOMr. Wayne Geoffrey Paterson

President & DirectorMr. David St. Denis

Head of AustraliaMr. Matthew McDonnell

Chief Financial OfficerMr. Brent A. Moen

M.P.H.Dr. Chris Meduri M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
L1 Capital Pty Ltd	10% Owner	Oct 06 '26	Buy	7.18	272,695	1,957,950	6,358,271	Oct 08 07:12 PM
L1 Capital Pty Ltd	10% Owner	Oct 05 '26	Buy	7.51	648,455	4,869,897	12,778,380	Oct 06 06:18 AM
L1 Capital Pty Ltd	10% Owner	Oct 02 '26	Buy	7.78	236,354	1,838,834	12,129,925	Oct 06 06:18 AM
L1 Capital Pty Ltd	10% Owner	Oct 01 '26	Buy	7.60	322,940	2,454,344	5,200,767	Oct 01 08:09 PM
L1 Capital Pty Ltd	10% Owner	Sep 30 '26	Buy	7.72	74,286	573,488	4,877,827	Oct 01 08:09 PM
L1 Capital Pty Ltd	10% Owner	Aug 28 '26	Sale	8.83	7,800	68,874	4,803,541	Sep 01 06:24 AM
St Denis David	Chief Operating Officer	Aug 19 '26	Option Exercise	5.65	60,000	339,000	161,082	Aug 20 07:49 PM
L1 Capital Pty Ltd	10% Owner	Aug 11 '26	Sale	9.30	375,815	3,495,080	4,811,341	Aug 12 06:13 AM
L1 Capital Pty Ltd	10% Owner	Aug 10 '26	Sale	9.10	251,844	2,291,780	5,187,156	Aug 12 06:13 AM
L1 Capital Pty Ltd	10% Owner	Aug 06 '26	Sale	8.10	174,721	1,415,240	5,439,000	Aug 10 07:24 AM
L1 Capital Pty Ltd	10% Owner	Aug 04 '26	Sale	8.30	480,608	3,989,046	5,628,302	Aug 06 06:48 AM
L1 Capital Pty Ltd	10% Owner	Aug 05 '26	Sale	8.23	14,581	120,002	5,613,721	Aug 06 06:48 AM
L1 Capital Pty Ltd	10% Owner	Aug 03 '26	Sale	8.10	475,693	3,853,113	6,108,910	Aug 04 06:23 AM
L1 Capital Pty Ltd	10% Owner	Jul 31 '26	Sale	8.15	48,711	396,995	6,584,603	Aug 04 06:23 AM
L1 Capital Pty Ltd	10% Owner	Jul 30 '26	Sale	8.20	558,633	4,580,791	6,633,314	Jul 31 06:25 AM
L1 Capital Pty Ltd	10% Owner	Jul 29 '26	Sale	8.04	155,505	1,250,260	7,191,947	Jul 31 06:25 AM
L1 Capital Pty Ltd	10% Owner	Jul 27 '26	Sale	8.19	232,817	1,906,771	7,556,183	Jul 29 06:40 AM
L1 Capital Pty Ltd	10% Owner	Jul 28 '26	Sale	8.09	208,731	1,688,634	7,347,452	Jul 29 06:40 AM
L1 Capital Pty Ltd	10% Owner	Jul 24 '26	Sale	8.13	23,000	186,990	7,789,000	Jul 28 08:34 AM
McDonnell Matthew	Chief Financial Officer	Jun 05 '26	Option Exercise	6.27	62,001	388,885	62,001	Jun 09 08:56 PM
Knight Susan Elizabeth	Director	Jun 02 '26	Buy	9.29	11,000	102,228	11,000	Jun 04 06:01 PM
L1 Capital Pty Ltd	10% Owner	Jan 22 '26	Buy	5.75	5,000,000	28,750,000	13,219,814	Feb 09 08:49 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AVR

Anteris Technologies Global Corp

Upgrade your Finviz experience